caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines

Archives

Current

November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011

 

Thursday, June 5, 2008
Updated news on FTY720 (Fingolimod) - one person has died, two with infections
 
Yikes. Thats all I can say right now.

"ZURICH, June 5 (Reuters) - Novartis AG (NOVN.VX: Quote, Profile, Research) said two patients taking its multiple sclerosis drug FTY720 in clinical trials had problems with infections and one died, but the role of the medicine in the cases was unclear.

It was recommended that clinical trials with the drug should continue as planned, the Swiss drugmaker said on Thursday.

"Novartis was recently notified of two infection-related incidents among FTY720 patients, including one fatality," the company said in a statement.

Novartis shares closed 0.7 percent lower at 54.45 Swiss francs on Thursday, with traders citing rumours that FTY720 trials had been stopped on safety concerns.

Shares of U.S.-based biotechnology company Biogen Idec (BIIB.O: Quote, Profile, Research), which sells MS drugs Avonex and Tysabri, were up 4 percent.

"The read-through is it would be good for Tysabri, it would be good for all the other MS drugs," said Leerink Swann analyst William Tanner.

"FTY720 I think historically has been looked at as being kind of a category killer for some of the injectable agents. If there are some issues that are compromising the study then that's going to be a problem," Tanner said.

Novartis said it was in talks with health authorities and experts to try and improve awareness of the risks of infections and how these may be reduced.

"Both cases involved confounding factors, including the use of very high doses of steroids in the first patient and the delayed use of antiviral therapy in the second patient," it said.

The company said FTY720's role in the cases was unclear but could not be excluded, since its mechanism of action leads to suppression of the immune system, which can increase the risk of infection.

Novartis had previously said it expected to submit the once-daily therapy, currently in late-stage trials, for approval before the end of 2009. (Additional reporting by Lewis Krauskopf in New York; editing by Rory Channing)"